| 29/07/26 | 16:02:53 | 29 Jul 2026 | | Holding(s) in Company |
| 27/07/26 | 07:00:09 | 27 Jul 2026 | | Result of Shareholder Analysis |
| 02/07/26 | 16:31:03 | 2 Jul 2026 | | Holding(s) in Company |
| 30/06/26 | 15:30:01 | 30 Jun 2026 | | Grant of Options |
| 26/06/26 | 07:00:03 | 26 Jun 2026 | | FINAL RESULTS |
| 25/06/26 | 07:00:03 | 25 Jun 2026 | | Phase 2 Clinical Trial Progress Update |
| 22/06/26 | 08:49:42 | 22 Jun 2026 | | Holding(s) in Company |
| 16/06/26 | 17:13:24 | 16 Jun 2026 | | Holding(s) in Company |
| 15/06/26 | 11:15:01 | 15 Jun 2026 | | Result of General Meeting |
| 04/06/26 | 07:00:05 | 4 Jun 2026 | | Significant Grant Award |
| 01/06/26 | 07:00:12 | 1 Jun 2026 | | Grant Award |
| 28/05/26 | 13:35:57 | 28 May 2026 | | Result of Retail Offer |
| 27/05/26 | 09:34:33 | 27 May 2026 | | Notice of General Meeting |
| 26/05/26 | 07:01:00 | 26 May 2026 | | Retail Offer to raise up to £100,000 |
| 26/05/26 | 07:00:14 | 26 May 2026 | | Placing of £2.5 million |
| 21/04/26 | 07:00:03 | 21 Apr 2026 | | Positive Preclinical Data for Docetaxel ChemoSeed |
| 02/04/26 | 07:00:05 | 2 Apr 2026 | | Board Changes |
| 25/03/26 | 07:00:01 | 25 Mar 2026 | | Phase 2 Clinical Trial Progress Update |
| 17/03/26 | 07:00:14 | 17 Mar 2026 | | Awarding of Orphan Drug Designation by the FDA |
| 20/01/26 | 07:00:10 | 20 Jan 2026 | | Japanese Patent Grant |
| 09/01/26 | 07:00:06 | 9 Jan 2026 | | Results of Shareholder Analysis |
| 15/12/25 | 14:29:32 | 15 Dec 2025 | | Result of Retail Offer |
| 10/12/25 | 07:25:01 | 10 Dec 2025 | | Retail Offer |
| 10/12/25 | 07:00:09 | 10 Dec 2025 | | Placing of £1,000,000 |
| 27/11/25 | 07:00:14 | 27 Nov 2025 | | Holding(s) in Company |
| 30/10/25 | 07:00:11 | 30 Oct 2025 | | US Orphan Drug Designation Application |
| 14/10/25 | 07:00:10 | 14 Oct 2025 | | Positive Preclinical Data in Prostate Cancer |
| 15/09/25 | 07:00:10 | 15 Sept 2025 | | Half Year Report |
| 12/09/25 | 07:00:18 | 12 Sept 2025 | | Notice of Interim Results and IMC Presentation |
| 01/09/25 | 07:00:10 | 1 Sept 2025 | | Approval for phase 2 clinical trial |
| 26/08/25 | 16:03:57 | 26 Aug 2025 | | Result of AGM |
| 26/08/25 | 07:00:06 | 26 Aug 2025 | | AGM Statement |
| 12/08/25 | 07:00:06 | 12 Aug 2025 | | GMP Manufacture of ChemoSeed |
| 04/08/25 | 17:45:00 | 4 Aug 2025 | | Notice of AGM and EMI Option Plan |
| 10/07/25 | 15:04:12 | 10 Jul 2025 | | Holding(s) in Company |
| 03/07/25 | 07:00:10 | 3 Jul 2025 | | Result of Retail Offer and Additional Placing |
| 01/07/25 | 16:41:13 | 1 Jul 2025 | | Update presentation on the IMC platform |
| 01/07/25 | 07:00:08 | 1 Jul 2025 | | Submission of CTA Application |
| 30/06/25 | 07:01:00 | 30 Jun 2025 | | Retail Offer |
| 30/06/25 | 07:00:11 | 30 Jun 2025 | | Placing |
| 13/06/25 | 07:00:09 | 13 Jun 2025 | | Final Results for the year ended 31 December 2024 |
| 09/06/25 | 07:00:10 | 9 Jun 2025 | | Best Paper Award |
| 03/06/25 | 07:00:07 | 3 Jun 2025 | | Establishment of Scientific Advisory Board |
| 07/04/25 | 11:46:21 | 7 Apr 2025 | | Director Dealing |
| 31/03/25 | 07:00:13 | 31 Mar 2025 | | Clinical Trial Update |
| 27/03/25 | 07:00:04 | 27 Mar 2025 | | Innovate UK Grant Award |
| 20/12/24 | 07:00:04 | 20 Dec 2024 | | Appointment of Specialist Clinical CRO |
| 18/12/24 | 07:00:02 | 18 Dec 2024 | | European Patent Grant |
| 19/09/24 | 07:00:03 | 19 Sept 2024 | | Interim Results |
| 09/09/24 | 07:00:10 | 9 Sept 2024 | | Notice of Interim Results & IMC Presentation |
